Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Apr;185(1-2):168-74.
doi: 10.1016/j.jneuroim.2007.01.011. Epub 2007 Feb 27.

Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response

Jerome J Graber  1 , David Ford, Min Zhan, Gordon Francis, Hillel Panitch, Suhayl Dhib-Jalbut
Affiliations
Randomized Controlled Trial

Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response

Jerome J Graber et al. J Neuroimmunol. 2007 Apr.

Abstract

We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-beta-1a 30 microg intramuscularly (IM) (n=8) or three-times-weekly (tiw) IFN-beta-1a 44 microg subcutaneously (SC) (n=7). Overall, IFN-beta treatment increased cellular IL-10 (p<0.01) levels and the ratios of cellular IL-10/IL-12p40 (p<0.01) and IL-10/IL-12p70 (p<0.02) while cellular IFN-gamma levels were reduced (p<0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p<0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p=0.031) and a decrease in cellular IL-12p70 (p<0.02). A decrease in cellular IFN-gamma was observed in responders (p=0.013). This is the first study that compares cytokine changes between the two IFN-beta regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum levels of interleukin-10 were lower in non-responders (as defined by cumulative unique MRI lesions) over the course of 24 weeks of IFN-β therapy compared to non-responders. Standard error bars are shown.
Figure 2
Figure 2
Levels of ex vivo cellular production of interleukin-12p70 over the course of 24 weeks of IFN-β therapy were lower in the group of non-responders compared to responders. Overlapping error bars are removed for clarity.
Figure 3
Figure 3
Levels of ex vivo cellular production of interferon-gamma decreased compared to baseline over the course of IFN-β therapy in the total group on any IFN-β therapy (p<0.001) and in the group of responders (p=0.013). Compared to non-responders, IFN-gamma levels were lower on treatment in responders (p=0.005). Overlapping error bars are removed for clarity.
See this image and copyright information in PMC

References

    1. Adikari SB, Pettersson A, Soderstrom M, Huang YM, Link H. Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis. Scand J Immunol. 2004;59:600–606. - PubMed
    1. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+T cell homeostasis by perforin and interferon-gamma. Science. 2000;290:1354–1358. - PubMed
    1. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol. 1999;45:247–250. - PubMed
    1. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger exacerbations? Acta Neurol Scand. 1988;78:318–323. - PubMed
    1. Beebe AM, Cua DJ, de Waal Malefyt R. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS) Cytokine and Growth Factor Reviews. 2002;12:403–412. - PubMed

Publication types

MeSH terms